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Abstract 
Introduction: Hepatic involvement by posttransplant 
lymphoproliferative disorders (PTLD) is an important 
but rarely investigated issue. In the current study, we 
aimed to pool data of cases of PTLD localization in liver 
(L-PTLD) among renal allograft recipients from different 
series to find new perspectives on the disease.  
Methods: We conducted a comprehensive search for the 
available data through PubMed and Google Scholar for 
reports of PTLD localization in the liver and surrounding 
lymph nodes in renal allograft recipients. Data of 232 
cases from 26 international studies have been pooled and 
reanalyzed. 
Results: Patients with L-PTLD were significantly more 
likely to be of male gender (P=0.02). Death due to PTLD 
was higher in L-PTLD patients (P=0.06). Disseminated 
PTLD, based on our definition, was significantly 
more prevalent in L-PTLD than in none-liver-PTLD 
(NL-PTLD) (P<0.001); the same finding was noted 
with multi-organ involvement which was significantly 
higher in L-PTLD (P<0.001). L-PTLD was significantly 
more likely to complicate heart (P=0.03), bone marrow 
(P=0.002), spleen (P=0.01), and kidney allograft 
involvement (P=0.04). 
Conclusion We conclude that renal transplant patients 
exhibiting liver localization for PTLD should be carefully 
followed for multi-organ involvement. Most notably, bone 
marrow biopsy should be considered, and evaluations for 
renal allograft, heart and spleen localization for PTLD 
should be executed. Due to the unfavorable characters 
of liver localization by PTLD in renal recipients, we 
propose higher levels of evaluations and follow up for 
these patients. Prospective studies with larger patient 
populations are needed to confirm our results. 
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Introduction 
Malignancies occurring post renal transplantation are 
important complications which seriously threat patient and 
graft survival [1-3]. Cancers complicating renal allograft 
recipients are considered as the third reason of death in 
this patient population, after cardiovascular diseases and 
infections [4]. Post transplant lymphoproliferative disease 
(PTLD) is a well-known and one of the most prevalent 
malignancies in transplant recipients and an important 
cause of morbidity and mortality in these patients. 
PTLD represents a wide spectrum of abnormal lymphoid 
proliferations taking place in the setting of ineffective 
T-cell function due to immunosuppression after organ 
transplantation. Viral infection most notable for Epstein-
Barr virus (EBV), type of organ transplantation, type and 
potency of immunosuppressive agents employed, and 
some demographic features of the organ recipients have 
all been associated with a higher incidence or outcome of 
PTLD in transplant era [5-9]. As mentioned above, the 
type of organ transplanted is a key factor in determining 
the incidence and features of PTLD. The incidence of 
PTLD is reportedly lowest in renal transplant recipients 
(0.8-2%) [10,11]. Moreover; it is generally considered that 
PTLD has a better outcome in renal allograft recipients 
compared to some other types of organ transplant patients 
such as heart graft recipients [12].
Complications of specific organs in various types of 
organ transplantation are of outmost relevance. Knowing 
susceptible organs for getting involved by PTLD in 
renal allograft recipients, we would be able to target our 
preventive endeavors more accurately, and to minimize 
morbidity and mortality in renal transplant population 
who develop PTLD in their disease course. On the 
other hand, revealing factors which play major roles in 
Hepatic Lymphomas Post Renal Transplantation May Signify Worse Disease  
Behavior: Analysis of Data from 26 International Studies
Hossein Khedmat*1, Saeed Taheri2
1. The Internist Research Center; Department of Internal Medicine; Baqiyatallah University of Medical Sciences, Tehran, Iran 
2. Dr Taheri Medical Research Group, Tehran, Iran 
Arab Journal of Nephrology and Transplantation
110
Khedmat and Taheri
inducing or preventing more aggressive forms of the 
disease or non-favorable histopathological features of 
PTLD lesion will also help us enhance our treatment 
strategies and improve outcomes. The overall number 
of liver involvement by PTLD in renal graft recipients 
is very limited and its cases are hidden in series related 
to single- or multi-center reports. In fact, until now, no 
study has focused on liver localization of PTLD in renal 
recipients; and to the extent of our knowledge, this is the 
first attempt on the issue. In the current study, we aimed 
to pool data of cases of PTLD localization in liver of renal 
recipients from different series to find new perspectives 
on the disease.  
Methods
Approach to the study: We conducted a comprehensive 
search for the available data through PubMed and Google 
Scholar for reports of PTLD localization in liver and 
surrounding lymph nodes in renal allograft recipients. 
Search terms used were “lymphoproliferative disorders 
+ renal transplantation + liver”, “lymphoproliferative 
disorders + kidney transplantation + hepatic localization”, 
“lymphoproliferative disorder + renal transplantation 
+ liver localization”, “lymphoproliferative disorders + 
kidney transplantation + liver”. In cases where we were 
not able to obtain the full text of the article, e-mails were 
sent to the correspondent authors requesting the article. 
Of the full texts obtained, we only included studies in 
which data on each patient was presented separately. 
To minimize selection bias, we only included studies 
reporting their series of patients from single- or multi-
center populations, and studies with any specific selection 
criterion were excluded from the analysis. Control patients 
were renal recipients in whom PTLD localization organ 
was not the liver. A standard questionnaire was developed 
to collect data from different published studies. The time 
between transplantation and PTLD onset was defined as 
the period between the graft and the first sign(s) of PTLD 
or diagnosis, depending on the study’s approach.
Study population: Twenty-six internationally-published 
studies [13-38] were found that met our criteria. A total of 
232 renal recipients with a documented PTLD site were 
included in the analysis; of whom 44 (19%) had liver 
PTLD (L-PTLD) and the remaining 188 (81%) patients 
had developed non-liver PTLD (NL-PTLD). EBV status 
was documented in 157 (67.7%) patients, of whom 113 
(72%) were reportedly positive. Because of different 
methodologies employed in the published studies enrolled 
into this study, some of our measures were not available 
for all the patients. So we tried to standardize the data. 
We recorded disseminated PTLD when it was reported 
by the study authors or if at least three different organs 
were involved by the PTLD (different lymph node areas 
were excluded from analysis due to lack of knowledge 
on how to categorize; unless they were concomitant with 
other organs involvement; or other authors specifically 
presented them as having disseminated disease). 
According to the above mentioned, data on disseminated 
PTLD was available for 167 patients (72%; 65 unreported 
data). Multi-organ involvement, defined as involvement 
of more than one organ (the second organ could be a 
lymphatic region), was reported in 216 patients (93.1%; 
16 unavailable data).
At PTLD onset, all patients were under immuno-
suppressive regimens consisting of varying combinations 
of azathioprine, prednisone, cyclosporine, mycophenolate 
mofetil, ATG/ALG and OKT3. A rather uniform 
approach was used to manage most of the included 
PTLD renal recipients. On diagnosis of PTLD, the first 
step in almost all reports was to decrease or discontinue 
immunosuppressive therapy; various regimens of 
chemotherapy with or without surgical interventions 
were also used for some patients.
Response to treatment: We defined response to treatment 
as any favorable change both in PTLD measures as well 
as the patient’s clinical condition. Data on response 
to treatment was reported for 114 patients (49.1%), of 
whom 71 (62.3%) responded to treatment and had a 
remission episode. To create a common standard across 
the studies, we defined a "remission" episode as when a 
patient was alive 24 months after PTLD onset (because 
all reported cases meeting this criterion had at least 
one confirmed remission episode). "No remission" was 
defined as when a patient died within the first month after 
PTLD onset (because there were no patients dying at the 
first post-transplant month that were reported to have 
any remission episode). According to these criteria, data 
on remission was available for 171 patients (73.7%), of 
whom 98 (57.3%) had at least one response to treatment, 
irrespective of their future disease course. Data on 
mortality was available for 219 patients (94.4%), of 
whom 133 (60.7%) died. We defined death due to PTLD 
when the authors stated it, death was within 6 months 
after onset, or death was reported to be due to PTLD 
treatment complications. Based on these criteria, 82 
patients (61.7% of reported deaths) died due to PTLD.
Statistical analysis: SPSS v.13.0 software was used 
for data analyses. Statistical comparisons between 
patient subgroups were performed using chi-square and 
Fisher’s exact tests for proportions, and the Student’s 
t-test for continuous data. Survival analysis was done 
with life tables, Kaplan-Meier method and log-rank 
test. Multivariate linear regression was used to detect 
independent association of various factors with the time 
interval between transplantation and PTLD onset. A 
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P-value of 0.05 was taken as the threshold for significance 
and of 0.1 was defined as relevance level.
Results
Overall, 232 cases of PTLD in renal allograft recipients 
were included. There were 133 (61.6%) male and 83 
(38.4%) female patients (16 unreported data). Mean 
age at onset was 39.9 ± 17.3 years. The mean interval 
between transplantation and the onset of PTLD was 58.3 
± 56.1 months and the mean follow up time after onset of 
PTLD was 23.9 ± 32.4 months. 
Characteristics of PTLD patients with and without liver 
involvement are summarized in Table-1. Chi-square test 
showed that patients with L-PTLD were significantly 
more likely to be of male gender (P=0.02). L-PTLD 
patients were comparable to NL-PTLD kidney recipients 
in their age (P=0.3), immunosuppressive drug basis 
(P=0.5), history of induction therapy (P=1.0), lymphoma 
cell type (P=0.3), histopathological features of PTLD 
lesions (P=0.8), time from transplantation to PTLD 
diagnosis (P=0.6), remission rates (P=0.1), and mortality 
rate (P=0.3). However, death due to PTLD was higher in 
L-PTLD patients (P=0.06). Disseminated PTLD, based 
on our definition, was significantly more prevalent in 
L-PTLD than in NL-PTLD (P<0.001); the same finding 
was achieved reporting multi-organ involvement which 
was significantly higher in L-PTLD (P<0.001).
Table-2 compares liver to NL-PTLD with respect to other 
organs involved. L-PTLD was significantly more likely 
to complicate heart (P=0.03), bone marrow (P=0.002), 
spleen (P=0.01), and kidney allograft involvement 
(P=0.04).
At the last follow up, 133 patients were dead. Using 
death by any cause as the outcome, log-rank test did not 
show any difference between the two groups in survival 
(P=0.4; Figure-1). Renal recipients with L-PTLD had 
a relevantly poorer PTLD-related outcome when only 
death due to PTLD (based on our definition) was used 
Table 1:  Characteristics of renal transplant recipients and their PTLD lesions, respecting hepatic localization of the PTLD
Variables L-PTLD NL-PTLD P value Available data
Age (years; mean ± SD) 37.4 ± 18.3 40.5 ± 17.1 0.3 230
Gender male (%) 32 (78) 101 (57.7) 0.02* 216
Time to PTLD development (months; mean ± SD) 53.8 ± 53.7 59.3 ± 56.8 0.6 219
Early onset (within first 12 months post TX) 12 (30.8) 47 (26.9) 0.7 214
Time from diagnosis to death (months;  mean ± SD) 11.3 ± 20 13.1 ± 20.3 0.7 113
Basic immunosuppression protocol 0.5 126
       Cyclosporine and Prednisolone 1(5.3) 2 (1.9)
       Azathioprine 14 (73.7) 80 (74.8)
       Mycophenolate Mofetil 1 (5.3) 15 (14)
       FK-506 3 (15.8) 10 (9.3)
Use of antibody induction 14 (70) 71 (67) 1.0 126
Multi organ involvement † 35 (81.4) 54 (31.2) <0.001* 216
Disseminated PTLD † 16 (48.5) 16 (11.9) <0.001* 167
Proportion of B cell 18 (81.8) 62 (91.2) 0.3 90
Morphology 0.8 135
       Early lesion (Plasmacytic hyperplasia) 1 (0.7) 3 (2.2)
       Polymorphic B cell lymphoma 12 (8.9) 41 (38.3)
       Monomorphic PTLD 14 (10.4) 54 (40)
       Hodgkin lymphoma 1 (0.7) 9 (6.7)
EBV positive 22 (78.6) 91 (70.5) 0.5 157
Remission episode 14 (43) 84 (60.4) 0.1 171
Data presented as number (%); PTLD: posttransplant lymphoproliferative disorders; L-PTLD: PTLD localization in the liver; NL-PTLD: non-liver PTLD
*   Statistically significant 
†   According to the criteria defined in the methods section
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as the outcome and other deaths were censored (P=0.1, 
Figure-2). One- and five-year survival rates for L-PTLD 
patients were 47% and 29%, respectively, compared to 
57% and 31%, respectively, for NL-PTLD controls.
Discussion
PTLD is a life threatening and not such a rare complication 
of transplantation with a very wide spectrum of clinical 
findings ranging from a focal and limited disease to 
a disseminated and rapidly progressive disorder. The 
frequency has been reported to range very widely 
depending on the organ transplanted and the type, dosage 
and duration of immunosuppressive agents employed for 
preventing rejection episodes, with a reported incidence 
range of less than 1% to 30% in different transplant 
populations [10, 39, 40]. In renal allograft recipients, 
the incidence of PTLD is reported to range from 0.7% 
to 2.6% in different series [18,41,42]. The outcome of 
PTLD in renal recipients has also been implicated to 
be better than other types of organ recipients, although 
the reported survival of renal recipients with PTLD in 
different series was quite variable. Several factors can 
play major roles in these disparities among which the 
histopathological features of the PTLD lesions, the type 
and number of organs involved by the cancer, therapeutic 
approaches employed for managing the disease, and 
physical status of the patients can be relevant. To clarify 
factors most likely to influence PTLD behavior, we need 
to study a large number of patients to analyze the potential 
contributing factors. Nevertheless, due to the very limited 
number of patients who provide information on each of 
the aforementioned, our knowledge on these would be 
essentially limited. So, in our PTLD questionnaire we 
tried to gather data of individual patients reported in 
different published series to make the largest possible 
population to investigate the impact of these factors. In 
a previous study, we analyzed hepatic graft involvement 
by PTLD in liver recipients [9] and in the present study; 
we explore the same organ complication by PTLD in 
renal allograft recipients. 
In the current study, we found that renal allograft recipients 
with liver PTLD localization are more likely to represent 
a disseminated disease, with a relatively poorer outcome, 
although the difference did not reach the significance 
level in the latter case. However, adding this to the higher 
rate of multi-organ PTLD in L-PTLD, this study shows a 
relatively more ominous disease in renal graft recipients 
whose liver has been complicated by PTLD compared to 
other disease localizations. In our previous study on liver 
transplant patients [9], consistent with the current study, 
we found that disseminated disease is significantly higher 
in patients representing hepatic localization for the PTLD; 
however, in that study, no outcome difference has been 
implicated. Moreover, liver recipients with hepatic PTLD 
were significantly older at the time of transplantation and 
had a shorter time to PTLD development, observations 
which have not been repeated in the current study on 
kidney recipients. Nuckols et al [43] have also found that 
Table 2: Frequency of the concomitant organs involved by PTLD in renal transplant recipients with and without hepatic 
involvement by the malignancy 
Involved organs L-PTLD NL-PTLD P value Available data
Orbital 0 1 (0.7) 1.0 193
Skeleton 0 5 (3.3) 0.4 192
Stomach 1 (2.7) 9(5.9) 0.7 189
Genitalia 2 (5) 3 (2) 0.3 191
CNS  3 (6.8) 24 (15.3) 0.2 201
Spleen 8 (20) 9 (6.1) 0.01* 188
Colon 4 (10) 5 (3.3) 0.09 193
Small intestine 3 (8.3) 27 (17.5) 0.2 190
Kidney 13 (33.3) 26 (17.1) 0.04* 191
Respiratory system 7 (18.9) 15 (10.4) 0.2 181
Bone marrow 8 (20) 6 (4) 0.002* 190
Skin 2 (4.9) 20 (13.2) 0.2 192
Heart 3 (10.7) 1 (1%) 0.03* 133
Data presented as number (%); PTLD: posttransplant lymphoproliferative disorders; L-PTLD: PTLD localization in the liver; NL-PTLD: non-liver PTLD
* statistically significant 
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almost all of their hepatic PTLD liver transplant cases 
were of early onset. Put together, these findings may 
indicate that this is a special character of liver PTLD in 
liver recipients. Moreover, Nuckols et al [43] reported a 
three times larger share of males in hepatic PTLD in liver 
recipients. In the current study, we also found that male 
renal recipients were significantly more likely to develop 
hepatic PTLD, although in our previous report on liver 
recipients, we did not find any gender disparity regarding 
liver involvement by the PTLD [9]. An interesting similar 
finding of the current study to our previous report on liver 
transplantation is heart and bone marrow involvement. 
In both, renal and liver recipients whose livers have 
been involved by PTLD, there were significantly higher 
tendencies for heart and bone marrow involvement 
by the PTLD, simultaneous to the liver disease. This 
finding is of outmost relevance; suggesting that liver 
involvement by lymphomas can be associated with the 
same complication in bone marrow and/or heart. These 
findings more intensively alert us to assess the heart and 
bone marrow of patients who have already developed 
lymphomas within their liver. Kidney allograft and 
spleen were also more likely to be complicated by the 
PTLD simultaneously with a liver involvement in our 
series of renal allograft recipients, a finding that seems to 
be special for kidney recipients, since it was not reported 
in liver transplant patients. 
This study has several limitations. Firstly, this is a 
retrospective review of studies that used different 
methodologies to report on PTLD. Secondly, the enrolled 
data gathered from those studies were not originally 
presented in the same way, and it was not possible to 
pool them without some manipulations. So, we had to 
standardize data to be able to compare them with each 
other. Standardization of data was not easy, and some 
people may not fully agree with us on the standardization 
methods employed in the current study. 
Conclusion
We conclude that renal transplant patients exhibiting 
liver localization for PTLD should be carefully evaluated 
for multi-organ involvement. Most notably, bone 
marrow biopsy should be considered, and evaluations for 
renal allograft, heart and spleen localization for PTLD 
should be executed. Due to the unfavorable characters 
of liver localization by PTLD in renal recipients, we 
propose higher levels of evaluations and follow up for 
these patients. Prospective studies with large patient 
populations are needed to confirm our results.
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